Luque, S, Hope, W 
ORCID: 0000-0001-6187-878X, Sorli, L, Munoz-Bermudez, R, Campillo, N, Barcelo-Vidal, J, Alvarez-Lerma, F, Horcajada, JP, Masclans-Enviz, JR, Neely, M et al (show 1 more authors)
(2021)
Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65 (6).
e02490-e02420.
Abstract
The high interindividual variability in the pharmacokinetics (PK) of linezolid has been described, which results in an unacceptably high proportion of patients with either suboptimal or potentially toxic concentrations following the administration of a fixed regimen. The aim of this study was to develop a population pharmacokinetic model of linezolid and use this to build and validate alogorithms for individualized dosing. A retrospective pharmacokinetic analysis was performed using data from 338 hospitalized patients (65.4% male, 65.5 [±14.6] years) who underwent routine therapeutic drug monitoring for linezolid. Linezolid concentrations were analyzed by using high-performance liquid chromatography. Population pharmacokinetic modeling was performed using a nonparametric methodology with Pmetrics, and Monte Carlo simulations were employed to calculate the 100% time >MIC after the administration of a fixed regimen of 600 mg administered every 12 h (q12h) intravenously (i.v.). The dose of linezolid needed to achieve a PTA ≥ 90% for all susceptible isolates classified according to EUCAST was estimated to be as high as 2,400 mg q12h, which is 4 times higher than the maximum licensed linezolid dose. The final PK model was then used to construct software for dosage individualization, and the performance of the software was assessed using 10 new patients not used to construct the original population PK model. A three-compartment model with an absorptive compartment with zero-order i.v. input and first-order clearance from the central compartment best described the data. The dose optimization software tracked patients with a high degree of accuracy. The software may be a clinically useful tool to adjust linezolid dosages in real time to achieve prespecified drug exposure targets. A further prospective study is needed to examine the potential clinical utility of individualized therapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | population pharmacokinetics, therapeutic drug monitoring, dose selection, Bayesian, individualized dosing, linezolid, pharmacokinetic software |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 28 Mar 2023 10:46 |
| Last Modified: | 28 Mar 2023 10:46 |
| DOI: | 10.1128/AAC.02490-20 |
| Open Access URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC83160... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3169299 |
Dimensions
Dimensions
